3rd Quarter - Report — PFIZER INC. for PFIZER INC. (2026)

Firm

PFIZER INC.

Client

PFIZER INC.

Income

—

Expenses

$3,600,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

H.R. 4101 - Cancer Drug Parity Act of 2025 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act S. 3510 - Biosimilar Inspection Modernization Act of 2025 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification FDA-2026-N-4699 - Expedited Investigational New Drug (IND) pilot program Section 301 Investigation re: Germany Issues FDA User Fee Agreements: 2027 PDUFA Cycle 340B Program Reform Prior Authorization Vaccine Access and Coverage FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage Pandemic and All-Hazards Preparedness Act (PAHPA)

Lobbyist	Covered position, as disclosed
FRANCISCO CARRILLO	—
EMILY MUELLER	—
MATTHEW STROIA	—
JENNIFER SWENSON WALTON	—
ANGELA BOOTHE WILES	—

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE; U.S. Trade Representative (USTR); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 5178 (119th), S. 3510 (119th), H.R. 4101 (119th)

Medicare/Medicaid MMM

H.R. 5256 - 340B ACCESS Act H.R. 9599 - SECURE 340B Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Vaccine Access and Coverage 340B Program Reform Hospital Outpatient Prospective Payment System (OPPS) Proposed Rule/Essential Medicines PBM Reform Drug Pricing Medicare/Medicaid Issues

Lobbyist	Covered position, as disclosed
FRANCISCO CARRILLO	—
EMILY MUELLER	—
MATTHEW STROIA	—
JENNIFER SWENSON WALTON	—
ANGELA BOOTHE WILES	—

Contacted: HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); SENATE

Bills named: H.R. 5256 (119th), H.R. 9599 (119th)

Trade (domestic/foreign) TRD

H.R. 9102 - Biotech Investment National Security Act (BINSA) Act: US Competitiveness, Biotechnology Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients FDA-2026-N-4699 - Expedited Investigational New Drug (IND) pilot program International Supply Chain Section 301 Investigation re: Germany Issues Foreign Freeriding Issues Non-Tariff Trade Barriers Global Health Competitiveness Issues Clinical Trial Issues

Lobbyist	Covered position, as disclosed
STEPHEN CLAEYS	—
EMILY MUELLER	—
CATHERINE ROBINSON	—
MATTHEW STROIA	—
JENNIFER SWENSON WALTON	—
ANGELA BOOTHE WILES	—

Contacted: State, Dept of (DOS); SENATE; Food & Drug Administration (FDA); U.S. Trade Representative (USTR); Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES

Bills named: H.R. 9102 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.